Veradermics, Incorporated cash flow to debt ratio of -1.79M% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Veradermics, Incorporated's free cash flow has decreased 202.37% from $-23.69M last year to $-71.63M, signaling decreasing performance

Veradermics, Incorporated's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Veradermics, Incorporated has insufficient data to evaluate this check.

Veradermics, Incorporated has a net cash position, so leverage is healthy.

Veradermics, Incorporated earns at least as much interest as it pays. Interest obligations are fully covered.

Veradermics, Incorporated has insufficient data to evaluate this check.

Veradermics, Incorporated's short-term assets of $152.49M exceed its short-term liabilities of $9.15M

Veradermics, Incorporated's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Veradermics, Incorporated's return on equity of -84.21%, is lower than 15.00%, indicating bad performance

Veradermics, Incorporated's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Veradermics, Incorporated has insufficient public price history to evaluate earnings stability.

Veradermics, Incorporated has negative free cash flow, indicating the company is burning cash rather than generating it

Veradermics, Incorporated has negative free cash flow, indicating cash burn

Veradermics, Incorporated's yearly earnings has decreased 164.25% since last year from $-26.49M to $-70.00M, signaling decreasing performance

Veradermics, Incorporated's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -13.49% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Veradermics, Incorporated has insufficient revenue history to calculate 3-year revenue CAGR.

Veradermics, Incorporated has insufficient public price history to evaluate revenue consistency.

Veradermics, Incorporated has insufficient public price history to evaluate ROE consistency.

Veradermics, Incorporated has insufficient data to evaluate this check.

Veradermics, Incorporated has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Veradermics, Incorporated is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Veradermics, Incorporated has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Veradermics, Incorporated has insufficient data to evaluate this check.

Veradermics, Incorporated has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Veradermics, Incorporated has a price-to-book ratio of 10.55x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Veradermics, Incorporated has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue